| 1 | 14th dresden symposium on | | | | | | | 2 | 0.70% |
| 2 | fda 510k clearance for | | | | | | | 2 | 0.70% |
| 3 | aesku receives fda 510k | | | | | | | 2 | 0.70% |
| 4 | receives fda 510k clearance | | | | | | | 2 | 0.70% |
| 5 | ifa system usa 04032018 | | | | | | | 1 | 0.35% |
| 6 | fda cleared with helios | | | | | | | 1 | 0.35% |
| 7 | 10th to 13 2019 | | | | | | | 1 | 0.35% |
| 8 | to 13 2019 dresden | | | | | | | 1 | 0.35% |
| 9 | 13 2019 dresden germany | | | | | | | 1 | 0.35% |
| 10 | march 2018 ndna crithidia | | | | | | | 1 | 0.35% |
| 11 | 2018 ndna crithidia luciliae | | | | | | | 1 | 0.35% |
| 12 | ndna crithidia luciliae now | | | | | | | 1 | 0.35% |
| 13 | crithidia luciliae now fda | | | | | | | 1 | 0.35% |
| 14 | luciliae now fda cleared | | | | | | | 1 | 0.35% |
| 15 | now fda cleared with | | | | | | | 1 | 0.35% |
| 16 | cleared with helios system | | | | | | | 1 | 0.35% |
| 17 | automated ifa system usa | | | | | | | 1 | 0.35% |
| 18 | usa 04032018 icap compatible | | | | | | | 1 | 0.35% |
| 19 | from september 10th to | | | | | | | 1 | 0.35% |
| 20 | system usa 04032018 icap | | | | | | | 1 | 0.35% |
| 21 | 510k clearance for ndna | | | | | | | 1 | 0.35% |
| 22 | clearance for ndna crithidia | | | | | | | 1 | 0.35% |
| 23 | for ndna crithidia luciliae | | | | | | | 1 | 0.35% |
| 24 | ndna crithidia luciliae with | | | | | | | 1 | 0.35% |
| 25 | crithidia luciliae with the | | | | | | | 1 | 0.35% |
| 26 | with the helios automated | | | | | | | 1 | 0.35% |
| 27 | helios automated ifa system | | | | | | | 1 | 0.35% |
| 28 | september 10th to 13 | | | | | | | 1 | 0.35% |
| 29 | dsa from september 10th | | | | | | | 1 | 0.35% |
| 30 | icap compatible ifa quality | | | | | | | 1 | 0.35% |
| 31 | clinical antinuclear antibody ana | | | | | | | 1 | 0.35% |
| 32 | registration for new icap | | | | | | | 1 | 0.35% |
| 33 | for new icap compatible | | | | | | | 1 | 0.35% |
| 34 | aesqc ifa quality control | | | | | | | 1 | 0.35% |
| 35 | ifa quality control products | | | | | | | 1 | 0.35% |
| 36 | quality control products for | | | | | | | 1 | 0.35% |
| 37 | control products for use | | | | | | | 1 | 0.35% |
| 38 | products for use with | | | | | | | 1 | 0.35% |
| 39 | for use with immunofluorescence | | | | | | | 1 | 0.35% |
| 40 | assays ifa including clinical | | | | | | | 1 | 0.35% |